Daniel Galbraith founded BioOutsource in 2007 with a team which included some former colleagues from Q-One Biotech, Europe’s leading CRO biosafety provider. Initially he worked as Head of Operations and more recently has taken the role as Chief Scientist where he has developed a successful team which is now seen as one of the leading providers for bioanalytical services globally and has gained a reputation for successful contract research in the biosimilar industry.
Prior to founding BioOutsource Daniel headed up the Biotechnology Service for Covance Laboratories Europe where he was in charge of their Biosafety Team. It was during his time in Covance that he first became involved with the bioanalysis of complex biologic molecules and eventually went on to develop services for Biosimilar molecules. He has also held senior positions in the fields of contract research (BioReliance Europe) and manufacturing (MedImmune) for some of the largest players within the Biotechnology industry. Daniel has a keen interest in Biosimilars and from his time with MedImmune working on the FluMist project he has retained an interest in virus vaccines and their testing to meet regulatory guidelines.
1. Why did you decide to do a webinar with Business Review Webinars?
We have been thinking of using webinars as a sales & marketing tool to complement our existing activities for a while and BRW offered the most comprehensive package that met all our needs.
2. What is one thing that’s key to BioOutsource’s success that somebody from outside the company wouldn’t know about?
The key to the company’s success is our unrivalled expertise in the field of Biosimilar Monoclonal Antibody characterisation. Due to our internal investment into this field, we have created a niche in the industry and offer the most comprehensive range of ‘off-the-shelf’ bioassays in the market, to meet the regulatory and quality requirements for Biosimilar products, reducing clients’ timelines and costs.
3.What is the most informative fact and what do you wish to achieve from the webinar?
Biological characterization is a complex, expensive and timely process, often fraught with costly errors that can ultimately lead to the failure of a development project. We seek to show our audience the importance of biological characterization in reducing the risk of development failure of Biosimilar Monoclonal Antibodies.
4. What do you most enjoy about your role?
The role of Chief Scientist allows me to work closely with a large number of companies to understand their products and where BioOutsource can partner with them to support the development of their projects. Key to the role is the challenge of understanding the mechanism of how these very complex drugs work and how we can provide assays which will characterize the drugs in a timely and cost effective manner.
5. What is your favourite movie or any you recommend to watch and why?
Favourite movie is 12 Angry Men, which is a very intense movie where one man stands against the rest of the jury as he doubts the verdict and finally triumphs through careful analysis to show the innocence of the accused. I think I like this movie as it shows where careful analysis of the facts points us to conclusions rather than the emotions which we are all guilty of.